1 |
Johnstone RW (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov, 1, 287-99.
DOI
|
2 |
Kelly TK, De Carvalho DD, Jones PA (2010). Epigenetic modifications as therapeutic targets. Nat Biotechnol, 28, 1069-78.
DOI
|
3 |
Kelotra S, Jain M, Kelotra A, et al (2014). An in silico Appraisal to Identify High Affinity Anti-Apoptotic Synthetic Tetrapeptide Inhibitors Targeting the Mammalian Caspase 3 Enzyme. Asian Pac J Cancer Prev, 15, 10137-42.
|
4 |
Lafon-Hughes L, Di Tomaso MV, Mendez-Acuna L, et al (2008). Chromatin-remodelling mechanisms in cancer. Mutat Res, 658, 191-214
DOI
|
5 |
Lauffer, Benjamin EL, Robert Mintzer, et al (2013). Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem, 288, 26926-43.
DOI
|
6 |
Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, et al (2007). Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res, 67, 6360-7
DOI
|
7 |
Mariadason JM (2008). HDACs and HDAC inhibitors in colon cancer. Epigenetics, 3, 28-37.
DOI
|
8 |
Nelder JA, Mead R (1965). A simplex method for function minimization. Comput J, 7, 308-13.
DOI
|
9 |
Piekarz RL, Sackett DL, Bates SE (2007). Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J, 13, 30-9
DOI
|
10 |
Shen L, Issa JP (2002). Epigenetics in colorectal cancer. Curr Opin Gastroenterol, 18, 68-73
DOI
|
11 |
Stevens FE, Beamish H, Warrener R, et al (2008). Histone deacetylase inhibitors induce mitotic slippage. Oncogene, 27, 1345-54
DOI
|
12 |
Thomsen R, Christensen MH (2006). MolDock: a new technique for high-accuracy molecular docking. J Med Chem, 49, 3315-21.
DOI
|
13 |
Xu WS, Perez G, Ngo L, et al (2005). Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res, 65, 7832-9
DOI
|
14 |
Yang JM, Chen CC (2004). Gemdock: A generic evolutionary method for molecular docking. Proteins, 55, 288-304.
DOI
|
15 |
Agrawal A, Murphy RF, Agrawal DK (2007). DNA methylation in breast and colorectal cancers. Mod Pathol, 20, 711-21
DOI
|
16 |
Bandaru S, Ponnala D, Lakkaraju C, et al (2014). Identification of high affinity non-peptidic small molecule inhibitors of mdm2-p53 interactions through structure-based virtual screening strategies. Asian Pac J Cancer Prev, 16, 3759-65.
|
17 |
Bandaru S, Tiwari G, Akka J, et al (2015). Identification of high affinity bioactive salbutamol conformer directed against mutated (thr164ile) beta 2 adrenergic receptor. Curr Top Med Chem, 15, 50-6.
DOI
|
18 |
Blair LP, Yan Q (2012). Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol, 31, 49-61.
|
19 |
Cai J, Wei H, Hong KH, et al (2015). Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1, 2, 4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents. Bioorg Med Chem, 23, 3457-71.
DOI
|
20 |
Bolden JE, Peart MJ, Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Disc, 5, 769-84
DOI
|
21 |
Cheng F, Li W, Zhou Y, et al (2012). Admet SAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model, 52, 3099-105.
DOI
|
22 |
Clayton AL, Hazzalin CA, Mahadevan LC (2006). Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell, 23, 289-96.
DOI
|
23 |
De Ruijter AJ, van Gennip AH, Caron HN, et al (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370, 737-49
DOI
|
24 |
Dokmanovic M, Clarke C, Marks PA (2007). Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res, 5, 981-9
DOI
|
25 |
Dokmanovic M, Marks PA (2005). Prospects: histone deacetylase inhibitors. J Cell Biochem, 96, 293-304
DOI
|
26 |
Fouladi M (2006). Histone deacetylase inhibitors in cancer therapy. Cancer Invest, 24, 521-7
DOI
|
27 |
Fraga MF, Ballestar E, Villar-Garea A, et al (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 37, 391-400
DOI
|
28 |
Glozak MA, Seto E (2007). Histone deacetylases and cancer. Oncogene, 26, 5420-32
DOI
|
29 |
Grant S, Easley C, Kirkpatrick P (2007). Vorinostat. Nat Rev Drug Discov, 6, 21-2.
DOI
|